2022
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellCohort StudiesHumansKidney NeoplasmsNeoplasm StagingQuality of LifeConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2020
Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care
Sterling J, Rivera-Núñez Z, Patel HV, Farber NJ, Kim S, Radadia KD, Modi PK, Goyal S, Parikh R, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care. Clinical Genitourinary Cancer 2020, 18: e643-e650. PMID: 32389458, PMCID: PMC7502425, DOI: 10.1016/j.clgc.2020.03.011.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansKidney NeoplasmsMinimally Invasive Surgical ProceduresNeoplasm StagingNephrectomyConceptsNational Cancer Data BaseRenal cell carcinomaPartial nephrectomyClinical T1 renal cell carcinomaT1 renal cell carcinomaInvasive surgeryUtilization of MISRegionalization of careLower socioeconomic groupsT1b renal massesClinical T1aCT1a patientsCT1a tumorsCT1b patientsCT1b tumorsRCC surgeryTreatment disparitiesCell carcinomaPatient populationRenal massesInvasive treatmentPatientsAcademic centersLogistic regressionPrivate insurance